Articles by Matthew J. Everly

Prevalence and Clinical Impact of Donor-Specific Alloantibody Among Intestinal Transplant Recipients

Cheng, Elaine Y.; Everly, Matthew J.; Kaneku, Hugo; More

Transplantation. 101(4):873-882, April 2017.

HLA and Risk of Diffuse Large B cell Lymphoma After Solid Organ Transplantation

Hussain, Shehnaz K.; Makgoeng, Solomon B.; Everly, Matthew J.; More

Transplantation. 100(11):2453-2460, November 2016.

Changes in Successive Measures of De Novo Donor-Specific Anti–Human Leukocyte Antigen Antibodies Intensity and The Development of Allograft Dysfunction

Dieplinger, Georg; Everly, Matthew J.; Rebellato, Lorita M.; More

Transplantation. 98(10):1097-1104, November 27, 2014.

Impact of IgM and IgG3 Anti-HLA Alloantibodies in Primary Renal Allograft Recipients

Everly, Matthew J.; Rebellato, Lorita M.; Haisch, Carl E.; More

Transplantation. 97(5):494-501, March 15, 2014.

Trends and Characteristics in Early Glomerular Filtration Rate Decline After Posttransplantation Alloantibody Appearance

Wu, Pingping; Everly, Matthew J.; Rebellato, Lorita M.; More

Transplantation. 96(10):919-925, November 27, 2013.

Incidence and Impact of De Novo Donor-Specific Alloantibody in Primary Renal Allografts

Everly, Matthew J.; Rebellato, Lorita M.; Haisch, Carl E.; More

Transplantation. 95(3):410-417, February 15, 2013.

Abrogation of Anti-HLA Antibodies via Proteasome Inhibition

Trivedi, Hargovind L.; Terasaki, Paul I.; Feroz, Aziz; More

Transplantation. 87(10):1555-1561, May 27, 2009.

Bortezomib Provides Effective Therapy for Antibody- and Cell-Mediated Acute Rejection

Everly, Matthew J.; Everly, Jason J.; Susskind, Brian; More

Transplantation. 86(12):1754-1761, December 27, 2008.